- Case report
- Open Access
Breast carcinoma and malignant melanoma metastasis within a single axillary lymph node
International Seminars in Surgical Oncology volume 3, Article number: 32 (2006)
A 58 year old lady presented with a right breast cancer and a prior history of malignant melanoma excised from the right chest wall eight years previously. An abnormal axillary lymph node resected contained features of both metastatic breast carcinoma and malignant melanoma. Following oncologic breast cancer management, the patient is well with no evidence of recurrence at three years.
There is an increased incidence of breast cancer as a second primary tumour in women previously diagnosed with a malignant melanoma . Any direct association is at best controversial  and common aetiogical factors remain elusive. One plausible link may be hormonal in origin as oestrogen receptors are expressed in up to half of malignant melanomas  and at least two-thirds of breast cancers.
There are isolated case reports of melanoma and carcinoma found together in the primary tumour mass in breast , lung , oral cavity [6, 7]. Cancer-to-cancer metastasis with evidence of melanoma metastases to primary renal cell carcinoma  is also documented. There is only one report of synchronous involvement in the metastatic axillary lymph node retaining the dual histology of the breast tumour exhibiting melanoma and carcinoma components . We report on a lymph node containing two different primary cancer types that may result in distinct clinical management and have different prognostic implications for the patient.
A 58 year old lady presented with a 2.5 cm right breast lump inferior to the nipple with skin tethering and a palpable malignant right axillary lymph node. She had excision of a right chest wall malignant melanoma Clark's level IV (1.18 mm maximum thickness) eight years prior. There were no palpable axillary nodes at that time. Mammogram, ultrasound and fine needle aspiration cytology of the breast lump confirmed breast cancer. Core biopsy of the right axillary lymph node showed high grade malignancy including pigmented cells, possibly originating from the malignant melanoma. She underwent right wide local excision and axillary nodal clearance. Histopathology revealed a 19 mm, grade 3 infiltrating ductal carcinoma of the breast of medullary phenotype with no lymphovascular invasion that was ER, PgR and HER-2 negative. Breast tumour cells in the primary cancer were positive for CAM 5.2, AE1, AE3 and EMA and negative for S100 and HMB45. Right axillary nodal clearance showed one out of nine lymph nodes contained metastatic cancer with a large area of necrosis and 2 distinct tumour types (Figure 1). One morphological type was of epithelial origin with cells arranged in cohesive sheets. These areas were positive for CAM 5.2, AE1, AE3 and EMA (Figure 2). Other areas were highly pleomorphic containing cells with prominent nucleoli arranged in loose dissociate clusters that were strongly positive for S100 protein and focally for HMB45; negative for EMA and CAM 5.2 (Figure 3). The lymph node metastases therefore contained features of metastatic breast carcinoma and malignant melanoma in the same metastatic focus. Staging CT of her thorax, abdomen and pelvis as well as a bone scan were negative for distant spread. The patient was treated with adjuvant chemotherapy for breast cancer with 5 fluorouracil, epirubicin and cyclophosphamide for six cycles followed by radiotherapy to the breast. She remains well with no evidence of breast cancer or melanoma recurrence three years later.
Early diagnosis and better treatment protocols have led to significant improvements in disease free and overall survival following a diagnosis of cancer. It is therefore becoming increasingly common for patients to be diagnosed with a second primary tumour in their lifetime, particularly in patients with primary malignant melanoma [1, 2]. The possible explanations include familial factors, the increasing natural lifespan of patients, and improved outcome following previous cancer treatment.
The primary breast cancer in our case did not contain melanoma cells that might have arisen through collision between two histologically different primary tumours, nor was there any pathological evidence of metaplasia, neuroendocrine differentiation or cancer to cancer metastases. The presence of two metastatic cell phenotypes in the axillary lymph node with different immunohistochemistry profiles is likely to have occurred in a metachronous fashion with the melanoma metastasis being detected incidentally during axillary dissection for breast carcinoma. The involved lymph node in probability represented the true sentinel node draining the skin of the chest wall and the breast. It is possible that melanoma micrometastases was dormant in the axillary lymph node and did not progress to clinical significance following the melanoma diagnosis. Melanoma micrometastases may therefore not be prognostically equivalent to overt nodal metastases and may reflect the natural history of melanoma micrometastases in the sentinel lymph node . Barnhill et al  demonstrated that melanoma micrometastases lack significant rates of proliferation, apoptosis and neo-vascularisation when compared with macrometastases as the angiogenic and lymphangiogenic factors may be suppressed by host immune responses.
Subsequent management and follow-up of patients such as ours depend on the competing risks and natural history of the two separate primary cancers. In this case, adjuvant breast cancer treatment was of priority with continued surveillance of the melanoma.
The common sentinel node draining the breast and the trunk skin probably reflects the dominant lymphatic pattern of ectodermal structures and adds to the anatomical evidence to support the concept of the first draining node to a regional basin. The application of new technologies to cancer staging has to be guided by the natural history of the various cancer types. Detection of regional metastases has different prognostic implications for breast cancer and melanoma and management decisions need to be made on evidence based clinical criteria rather than any incidental findings.
Gutman M, Cnaan A, Inbar M, Shafir R, Chaitchik S, Rozin RR, Klausner JM: Are malignant melanoma patients at higher risk for a second cancer?. Cancer. 1991, 68 (3): 660-5. 10.1002/1097-0142(19910801)68:3<660::AID-CNCR2820680337>3.0.CO;2-5.
Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T: Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996, 73 (2): 255-9.
Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK: Estrogen receptor in malignant melanoma. Journal of Clinical Oncology. 1987, 5 (8): 1256-1261.
Padmore RF, Lara JF, Ackerman DJ, Gales T, Sigurdson ER, Ehya H, Cooper HS, Patchefsky AS: Primary combined malignant melanoma and ductal carcinoma of the breast. Cancer. 1996, 78 (12): 2515-2525. 10.1002/(SICI)1097-0142(19961215)78:12<2515::AID-CNCR11>3.0.CO;2-Z.
Ueyama T, Tsuru T, Tsuneyoshi M, Suelshi K, Sibuya T, Fukuda T: Primary collision neoplasm of malignant melanoma and adenocarcinoma in the lung. A case report. Pathol Res Pract. 1993, 189: 178-83.
Sirsat MV, Shrikhande SS: Collision tumour in the oral cavity. Indian J Pathol Bacteriol. 1996, 9 (4): 340-3.
Davis JP, Maclennan KA, Schofield JB, Watkinson JC, Gluckman P: Synchronous primary mucosal melanoma and mucoepidermoid carcinoma of the maxillary antrum. J Laryngology and Otology. 1991, 105: 370-2.
Singh EO, Benson RC, Wold LE: Cancer-to-cancer metastases. J Urol. 1984, 132: 340-2.
Giblin AV, Hayes AJ, Thomas JM: The significance of melanoma micrometastases in the sentinel lymph node. Eur J Surg Oncol. 2005, 31 (10): 1103-4. 10.1016/j.ejso.2005.06.006.
Barnhill RL: The biology of melanoma micrometastases. Recent Results Cancer Res. 2001, 158: 3-13.
About this article
Cite this article
Carswell, K.A., Behranwala, K.A., Nerurkar A, A. et al. Breast carcinoma and malignant melanoma metastasis within a single axillary lymph node. Int Semin Surg Oncol 3, 32 (2006). https://doi.org/10.1186/1477-7800-3-32
- Breast Cancer
- Sentinel Node
- Axillary Lymph Node
- Melanoma Metastasis